164 subscribers
Go offline with the Player FM app!
3268 How CellVoyant is Predicting Cell Outcomes Before They Happen with AI
Manage episode 480684022 series 2391590
In today’s episode, I had the opportunity to speak with Rafael Carazo Salas, a scientist, entrepreneur, and the CEO and founder of CellVoyant. This is a conversation that goes beyond the hype around AI to reveal how machine learning is reshaping the future of healthcare in ways that are both profound and immediate.
CellVoyant, a spinout from the University of Bristol, is using AI and advanced imaging technology to solve one of the most persistent challenges in biotech: the cost, time, and complexity involved in developing cell therapies.
Rafael explained how his team is applying real-time microscopy and predictive AI to monitor and guide cell behavior. This approach doesn’t rely on invasive techniques that destroy the very cells being studied. Instead, it enables a clearer path forward in cell therapy development by understanding how cells behave and adapt over time.
We explored several impactful examples, from CAR-T therapies for blood cancers to emerging treatments for Parkinson’s disease and type 1 diabetes. Rafael drew comparisons to Google Maps, describing how CellVoyant’s platform builds dynamic roadmaps for cell development, allowing scientists to correct course in real time. It’s a shift in how we think about drug development, one that has the potential to lower costs and increase access to life-saving treatments.
Beyond the science, Rafael shared his insights on the UK’s biotech ecosystem, the role of academic spinouts, and why now is a strategic moment for the UK to establish itself as a global leader in AI-powered biotech. As political and economic conditions shift in other parts of the world, he sees a window of opportunity to attract talent, drive innovation, and strengthen commercialisation.
So how far can AI go in transforming biotech, and what role will companies like CellVoyant play in making advanced therapies available to all? Tune in to find out.
2111 episodes
Manage episode 480684022 series 2391590
In today’s episode, I had the opportunity to speak with Rafael Carazo Salas, a scientist, entrepreneur, and the CEO and founder of CellVoyant. This is a conversation that goes beyond the hype around AI to reveal how machine learning is reshaping the future of healthcare in ways that are both profound and immediate.
CellVoyant, a spinout from the University of Bristol, is using AI and advanced imaging technology to solve one of the most persistent challenges in biotech: the cost, time, and complexity involved in developing cell therapies.
Rafael explained how his team is applying real-time microscopy and predictive AI to monitor and guide cell behavior. This approach doesn’t rely on invasive techniques that destroy the very cells being studied. Instead, it enables a clearer path forward in cell therapy development by understanding how cells behave and adapt over time.
We explored several impactful examples, from CAR-T therapies for blood cancers to emerging treatments for Parkinson’s disease and type 1 diabetes. Rafael drew comparisons to Google Maps, describing how CellVoyant’s platform builds dynamic roadmaps for cell development, allowing scientists to correct course in real time. It’s a shift in how we think about drug development, one that has the potential to lower costs and increase access to life-saving treatments.
Beyond the science, Rafael shared his insights on the UK’s biotech ecosystem, the role of academic spinouts, and why now is a strategic moment for the UK to establish itself as a global leader in AI-powered biotech. As political and economic conditions shift in other parts of the world, he sees a window of opportunity to attract talent, drive innovation, and strengthen commercialisation.
So how far can AI go in transforming biotech, and what role will companies like CellVoyant play in making advanced therapies available to all? Tune in to find out.
2111 episodes
All episodes
×
1 3301: How DigiCert Is Redefining Digital Trust 32:36

1 3300: How IBM Is Building AI That Works for Business With IBM UK & Ireland Chief Executive, Leon Butler 30:23

1 3299: How Oyster HR Is Using AI to Redefine Employment Infrastructure 26:33

1 3297: TheyDo and the Tech Helping Brands Map & Manage Journeys 23:57

1 3296: Rethinking FinOps with DoiT Ahead of FinOps X 33:28

1 3295: Ledger, Crypto and the Battle for Digital Sovereignty 38:43

1 3294: How Pico MES Is Closing the Digital Gap in Manufacturing 43:40

1 3293: The Red Cross Digital Emblem: A New Era of Cyber Protection for Humanitarian Organizations 30:02

1 3292: Exploring the Future of AI, Financial Innovation and Money20/20 Europe 26:44

1 3291: How Panzura is Modernizing Hybrid Cloud for AI Workloads 31:12

1 3290: HQO and the Future of Human-Centric Smart Buildings 36:15

1 3289: StorX Network and the Future of Private Cloud Storage 25:02

1 3288: MLPerf vs Moore’s Law: Redefining AI Progress 39:13

1 3287: Data-Driven Marketing: How Converge Uses Technology to Drive Growth 26:18
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.